Rampant Counterfeit ZYN Nicotine Pouches in U.S. Market

Aug.16.2024
Rampant Counterfeit ZYN Nicotine Pouches in U.S. Market
Fake ZYN nicotine pouches flood the US market, posing serious risks to consumers and prompting concerns about brand integrity.

Special announcement:

Rampant Counterfeit ZYN Nicotine Pouches in U.S. Market
The whistleblower claimed that they have never found a genuine box of ZYN in the four states they visited.


The information in this article comes from online users, and FIRSTS is unable to verify the authenticity of this information. We are simply providing industry news and information quickly and widely.

Rampant Counterfeit ZYN Nicotine Pouches in U.S. Market
An American wholesaler consulted the informant in this article about the source of ZYN products. | Image source: Informant


If you have any objections to the revelations in this article or would like to communicate with us, please feel free to contact us through the following email address: info@2firsts.com.

Rampant Counterfeit ZYN Nicotine Pouches in U.S. Market
Click on the image to read "The Mystery of Counterfeit Nicotine Pouches: Why are Fake Products Proliferating? How to Combat Counterfeit Goods Displacing Genuine Ones?


This article is not responsible for the accuracy of the information disclosed. Readers should maintain a rational mindset while reading and carefully evaluate the information.


In the highly competitive and saturated e-cigarette market, nicotine pouches are gaining attention as an emerging area. However, due to technology patents protection, technological barriers, and regulatory policy uncertainty, the market for nicotine pouches is flooded with counterfeit products. Addressing this issue, 2FIRSTS conducted a thorough analysis in their previous report, "Suspicions of Counterfeiting in the Nicotine Pouch Industry: Why are Fake Products So Common? How to Address the Problem of Bad Money Driving Out Good Money?" The report revealed the risks of counterfeit and compliance in the rapidly growing nicotine pouch market, highlighting the complexities of the market.


After the article was published, a senior figure in the nicotine pouch industry who is currently visiting the US market shared his observations with 2FIRSTS. According to him, counterfeit versions of the well-known brand ZYN are rampant in New York, New Jersey, Virginia, and Arizona. He described the situation as alarming, stating that during his visits he did not come across a single authentic box of ZYN in any of these four states.


Counterfeit ZYN products are now being sold in several states in the United States at twice the price of VELO.


According to reports, in the American market, in addition to the ZYN brand, there are also other nicotine pouch brands such as ROGUE, VELO, ON!, and FRE. However, ZYN is not only the most widely available brand, but also the most rampant in terms of counterfeit products.


ZYN, acquired by Philip Morris International (PMI) from Swedish Match, saw its shipment volume of nicotine pouches reach 266.7 million cans in the first half of 2024, representing a 63.5% year-on-year increase, as indicated in its performance report.


The sharp increase in sales has led to a market imbalance of supply and demand. According to industry insiders, counterfeit ZYN products are widely distributed in various retail terminals such as convenience stores, tobacco shops, e-cigarette stores, and gas stations, with prices ranging from $6.99 to $9.99, similar to authentic products. However, the nicotine pouch brand VELO, owned by British American Tobacco, is priced at only $4.99, while FRE is priced at just $2.99.


The appearance is so real that it is difficult to distinguish, and the taste is described as "sugar-like.


What is even more worrying is that these counterfeits closely resemble the authentic products in terms of appearance, including box design, color combinations, and material textures, making it almost impossible to distinguish between the two. As a result, not only do average consumers struggle to identify the authenticity of products, but even most shop owners lack a clear understanding of the authenticity of the goods they sell.


Although distinguishing between real and fake ZYN can be difficult, industry insiders have provided a viable method. They point out that the bottom of the box of ZYN contains a QR code, which consumers can scan after purchasing the genuine product to directly access the official ZYN website. If the QR code scanned is for a counterfeit product, it will first redirect to an unknown website before potentially redirecting to the ZYN official website.


In addition, authenticity can also be discerned through the use of experience. According to him, counterfeit ZYN products have significant differences in user experience compared to the genuine ones, with the fakes giving a feeling "like candy." He speculated that these imitation products may not contain any nicotine at all, or only contain a small amount of nicotine, in order to reduce production costs.


Where do counterfeit products come from?


In the article "Suspicions of Nicotine Pouch Counterfeiting: Why are Fake Products Frequently Emerging? How to Combat Bad Money Drives Out Good Money?" 2FIRSTS once held in-depth discussions with industry experts on this issue. At that time, several industry insiders pointed out that China is one of the sources of counterfeit nicotine pouches.


According to the investigation conducted by the aforementioned sources, the conclusion is unanimous - the majority of counterfeit ZYN products originate from manufacturers in China. Some American wholesalers even inquired about the supply chain for ZYN pouches and bluntly stated, "Everyone making zyn in china now.


However, it is understood that ZYN's official production facility is located in Sweden. Philip Morris International (PMI) announced in July of this year that a new ZYN production plant will be built in Colorado, USA. Currently, there are no officially authorized contract factories in China.


This phenomenon has already raised concerns among some industry insiders in the United States, who worry that as brands continue to expand, the issue of counterfeit goods may also arise. As mentioned by the aforementioned individuals, a client who has already obtained PMTA certification raised the question to him: if they were to manufacture products in China, would they also face the risk of being counterfeited as their business grows.


An expert in the emerging tobacco industry stated that from an industry perspective, nicotine pouches as a new form of nicotine consumption have always been controversial, especially in terms of their use by young people and health impacts. The issue of counterfeit products may exacerbate these concerns, prompting regulatory agencies and public health experts to more closely scrutinize this market.


At the same time, for legitimate manufacturers, the proliferation of counterfeit goods could damage their brand image and force them to invest more resources to protect their intellectual property and consumer rights.


For industries in China, this approach will lead to a severe lack of trust in Chinese-made nicotine pouch products overseas, causing incalculable damage to the industry's progress and development.


2FIRSTS will continue to monitor the counterfeit nicotine pouch incident and provide timely updates on the latest developments.


We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Special Report | From New York to Washington: How FDA’s Tobacco Center Is Reworking Product Review
Special Report | From New York to Washington: How FDA’s Tobacco Center Is Reworking Product Review
FDA’s Center for Tobacco Products is reshaping how it approaches tobacco product review. Based on 2Firsts’ on-site reporting in New York and Washington, this report traces CTP’s emerging direction: stronger links between PMTA and tobacco harm reduction, more category-specific review, greater emphasis on decision-relevant science, more predictable timelines and expanded use of sPMTA for product modifications. CTP also acknowledged major constraints, including just nine PMTA review teams, persistent backlogs and limits on hiring capacity.
Regulations
Oct.08
2Firsts Compliance Solutions Hosts PMTA Briefing on FDA Review Signals After JUUL2 Authorization
2Firsts Compliance Solutions Hosts PMTA Briefing on FDA Review Signals After JUUL2 Authorization
Following recent FDA authorizations for JUUL2 and ZYN ULTRA, 2Firsts Compliance Solutions held an online PMTA briefing on Sept. 4 to examine what the decisions may signal about review efficiency, scientific evidence and U.S. market access. Nearly 30 participants from brands, manufacturers, compliance service providers and investment firms joined the discussion.
2Firsts Events
Sep.06
Product | PMJ Adds Bold Ruby to IQOS ILUMA i Lineup in Japan, Convenience-Store Rollout Starts Sept. 29
Product | PMJ Adds Bold Ruby to IQOS ILUMA i Lineup in Japan, Convenience-Store Rollout Starts Sept. 29
Philip Morris Japan (PMJ) launched Bold Ruby as a new regular color for the IQOS ILUMA i and IQOS ILUMA i ONE in Japan on September 16, 2026, priced at JPY 6,980 and JPY 3,980, respectively. Initial sales began through IQOS online and physical channels, with convenience stores and selected tobacco retailers set to follow from September 29. Bold Ruby is a regular rather than limited-edition colorway and is available for the ILUMA i and ILUMA i ONE, but not the ILUMA i PRIME. The release does not involve changes to the devices' core hardware or functions.
Sep.22
UK Extends Age-18 Rules to Zero-Nicotine Vapes and Nicotine Pouches From Oct. 29, Bans Vending Machines and Promotional Giveaways
UK Extends Age-18 Rules to Zero-Nicotine Vapes and Nicotine Pouches From Oct. 29, Bans Vending Machines and Promotional Giveaways
Key provisions of the UK's Tobacco and Vapes Act 2026 will take effect on Oct. 29, extending an age-18 sales restriction to all vaping and non-medicinal nicotine products. In England, Wales and Northern Ireland, the change brings zero-nicotine vapes within statutory age-of-sale rules and also covers products including nicotine pouches, strips and pearls. The law will also prohibit proxy purchasing for under-18s, consumer-facing vending machines, promotional giveaways and substantial discounts intended to promote vaping and nicotine products.
Regulations
Oct.10
Special Report | Altria Subsidiaries Sue FDA to Vacate 2021 PMTA Rule as Agency Moves to Speed Reviews
Special Report | Altria Subsidiaries Sue FDA to Vacate 2021 PMTA Rule as Agency Moves to Speed Reviews
2Firsts reviewed the original federal court complaint filed by Altria subsidiaries Helix Innovations and NJOY on Sept. 2 challenging FDA’s 2021 PMTA rule. The lawsuit questions whether FDA’s review process complies with the Tobacco Control Act’s 180-day timeline, even as the agency moves to accelerate PMTA reviews and issues more marketing orders. Drawing on the complaint, FDA records, government audits and recent court rulings, 2Firsts examines the legal arguments, supporting evidence and potential implications for the U.S. tobacco review system.
Regulations
Sep.03
On-Site Report | CTP Details PMTA Backlog, 180-Day Review Goal and sPMTA Process
On-Site Report | CTP Details PMTA Backlog, 180-Day Review Goal and sPMTA Process
FDA’s Center for Tobacco Products detailed new PMTA review data and process changes at the 2026 FDLI conference. Pending PMTAs fell from about 450,000 at the start of 2025 to 135,000 by September 2026. CTP also discussed its 180-day review goal, current sPMTA pilot, alternate-supplier planning, more than 50,300 pending SE reports, and lessons from the nicotine pouch pilot already being applied to ENDS review.
Regulations
Oct.07